Guidance Needed To Explain Scope Of MDR’s Confusing Clinical Investigations Clause
Article 61(5) of the EU’s Medical Device Regulation gives certain manufacturers an exemption from having to perform clinical investigations by demonstrating equivalence to other companies’ products. But to whom does it apply and who could actually make use of it? Dr. Maria Donawa explains why clarification is urgently needed.
You may also be interested in...
Growing evidence demonstrates the one-year delay to the Medical Device Regulation, plus the expansion of the scope of products that could remain on the market beyond the MDR date of application, have simply pushed problems to 2024.
The European Commission’s just updated Rolling Implementation Plan for the MDR and IVDR shows delays in key structures for high-risk IVDs. Recent guidance clarifies how and when these products can still proceed to CE marking.
Warnings gathered pace around a year ago that EU MDR implementation delays would see hundreds, even thousands, of products removed from market. MedTech Europe’s Oliver Bisazza explains how a disastrous situation was avoided but industry is still in choppy waters.